Sun Pharma nears $12bn Organon bid

Sun Pharma is trying to pull off a deal that would be bigger than many Indian drugmakers’ entire annual sales: a roughly $12 billion bid for Organon, the New Jersey company spun out of Merck in 2021. Reports on April 10 said Sun had finished due diligence, lined up banks, and was moving toward a binding offer. (economictimes.indiatimes.com) (outlookbusiness.com) The market reaction was instant because Organon is small enough for a bid like that to transform both companies at once. MarketWatch reported Organon shares jumped in premarket trading after the bid report, which is what happens when investors think a buyer may pay far above the last traded price. (marketwatch.com) Organon is not a laboratory-stage biotech with one miracle drug. It is a cash-generating medicines company built around women’s health, biosimilars, and older established brands, and it reported $6.2 billion of revenue and $1.91 billion of adjusted earnings before interest, taxes, depreciation, and amortization for 2025. (organon.com) That mix explains why Sun is interested. Sun’s own 2025 fiscal year sales were 520.4 billion Indian rupees, with $1.216 billion from its global specialty business, so buying Organon would add a large overseas portfolio in categories where Sun wants more scale, especially branded products sold outside India. (sunpharma.com) Organon also comes with problems, and those problems are part of the price. Its fourth-quarter 2025 women’s health revenue fell 15% to $398 million, while total fourth-quarter revenue fell 5% to $1.507 billion, showing that Sun would not be buying a fast-growing asset but a business that needs stabilizing. (organon.com) One pressure point is Nexplanon, Organon’s contraceptive implant. Organon said fourth-quarter Nexplanon sales fell 20% excluding currency effects because of changes in United States wholesaler practices, access restrictions, and higher rebates, which means the buyer has to believe it can stop that slide or make the rest of the portfolio matter more. (organon.com) The other pressure point is debt. Outlook Business reported Organon has about $9.5 billion of debt from its separation from Merck, so a buyer is not just paying the equity check on the front page but also inheriting a balance sheet that has already been forcing deleveraging moves. (outlookbusiness.com) That is why the financing list matters almost as much as the bid itself. Reports say JPMorgan, Mitsubishi United Financial Group, Standard Chartered, and Citigroup are involved, which suggests Sun is preparing a mix of cash, debt, and bridge financing rather than writing a simple cash check from its own balance sheet. (outlookbusiness.com) This is also not a one-buyer auction. The Economic Times and follow-on reports said two other global suitors remain in contention, with Morgan Stanley exploring options for Organon, so Sun may have to decide how much it is willing to pay for scale before the math stops working. (economictimes.indiatimes.com) (outlookbusiness.com) If Sun wins, the deal would test a strategy Indian drugmakers have talked about for years: move beyond selling lower-cost copies of medicines and own bigger branded franchises overseas. Sun already calls itself a leading specialty generics company with operations in more than 100 countries, and Organon would add a ready-made global sales base instead of a slow country-by-country buildout. (sunpharma.com) (outlookbusiness.com) The whole contest now comes down to one question with a lot of zeros in it. Is Organon a $6.2 billion revenue platform that Sun can fix and refinance, or a debt-heavy portfolio whose falling women’s health sales turn a record Indian takeover into an expensive lesson. (organon.com) (economictimes.indiatimes.com)